C4 Therapeutics, Inc. (CCCC)
NASDAQ: CCCC · Real-Time Price · USD
6.45
+0.84 (14.97%)
At close: Nov 4, 2024, 4:00 PM
6.31
-0.14 (-2.17%)
After-hours: Nov 4, 2024, 7:38 PM EST
C4 Therapeutics Ratios and Metrics
Market cap in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Current | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
| Nov '24 Nov 4, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
| Market Capitalization | 455 | 278 | 289 | 1,566 | 1,426 | - | |
| Market Cap Growth | 331.96% | -3.60% | -81.55% | 9.83% | - | - | |
| Enterprise Value | 238 | 104 | 11 | 1,108 | 1,506 | - | |
| Last Close Price | 6.45 | 5.65 | 5.90 | 32.20 | 33.13 | - | |
| PE Ratio | - | -2.12 | -2.25 | -17.67 | -5.68 | - | |
| PS Ratio | 12.36 | 13.41 | 9.29 | 34.20 | 42.95 | - | |
| PB Ratio | 1.88 | 1.13 | 1.00 | 4.02 | 5.08 | - | |
| P/FCF Ratio | -5.52 | -2.57 | -2.59 | -17.74 | -21.00 | - | |
| P/OCF Ratio | -5.55 | -2.61 | -2.73 | -18.00 | -21.20 | - | |
| EV/Sales Ratio | 7.07 | 5.02 | 0.35 | 24.20 | 45.36 | - | |
| EV/EBITDA Ratio | -1.46 | -0.76 | -0.09 | -13.74 | -25.59 | - | |
| EV/EBIT Ratio | -1.44 | -0.75 | -0.08 | -13.49 | -24.91 | - | |
| EV/FCF Ratio | -2.35 | -0.96 | -0.10 | -12.56 | -22.17 | - | |
| Debt / Equity Ratio | 0.28 | 0.29 | 0.30 | 0.11 | 0.08 | -14.20 | |
| Debt / FCF Ratio | -0.94 | -0.65 | -0.78 | -0.49 | -0.34 | 0.25 | |
| Asset Turnover | 0.09 | 0.05 | 0.07 | 0.10 | 0.13 | 0.16 | |
| Quick Ratio | 6.14 | 6.21 | 6.23 | 6.15 | 8.58 | 2.83 | |
| Current Ratio | 6.31 | 6.34 | 6.46 | 6.36 | 8.69 | 2.88 | |
| Return on Equity (ROE) | -46.00% | -49.50% | -37.76% | -25.03% | -47.41% | -225.25% | |
| Return on Assets (ROA) | -20.61% | -21.53% | -17.27% | -11.32% | -14.58% | -16.74% | |
| Return on Capital (ROIC) | -24.44% | -25.06% | -20.02% | -13.95% | -23.87% | -75.74% | |
| Earnings Yield | -23.17% | -47.58% | -44.37% | -5.36% | -4.65% | - | |
| FCF Yield | -15.72% | -38.98% | -38.58% | -5.64% | -4.76% | - | |
| Buyback Yield / Dilution | -31.51% | -1.59% | -6.12% | -304.93% | -728.80% | -6.09% | |
| Total Shareholder Return | -31.51% | -1.59% | -6.12% | -304.93% | -728.80% | -6.09% | |
Source: S&P Capital IQ. Standard template.
Financial Sources.